Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty
Summary
Yes. For these two fields, I would enter the following in English, based on your study protocol. 1\. Brief Summary Copy and paste: This study aims to compare three thromboprophylaxis regimens in adults undergoing primary total knee arthroplasty: rivaroxaban 10 mg once daily, apixaban 2.5 mg twice daily, and low-molecular-weight heparin (LMWH) once daily. The study will assess venous blood flow in the lower limbs using Doppler ultrasound and determine whether blood flow differs between the three treatment groups. Participants will be randomly assigned to one of the three treatment groups and followed for 28 days after surgery. Doppler ultrasound examinations will be performed at baseline and on Days 7, 15, 21, and 28. Additional assessments will include rehabilitation progress, postoperative bleeding, suspected venous thromboembolism, cardiovascular complications, and other postoperative complications. The study is being conducted at the Department of Anesthesiology, Principal Military Hospital of Instruction of Tunis.
Timeline
- Start
- 2026-09-15
- Primary completion
- 2027-04-15
- Completion
- 2027-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apixaban | Small molecule | 2.5 mg | Oral |
| Comparator | Enoxaparin sodium | Other / unclassified | 40 mg | — |
| Comparator | Enoxaparin sodium | Other / unclassified | 60 mg | — |
| Subject | Rivaroxaban | Other / unclassified | 10 mg | Oral |
Indications
No indication recorded.